Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Alemtuzumab Versus Thymoglobulin Induction Therapy in Kidney and Pancreas Transplantation

NCT00331162 is registered in ClinicalTrials.gov with Wake Forest University Health Sciences as lead sponsor.

NCT NCT00331162
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00331162 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Alemtuzumab Versus Thymoglobulin Induction Therapy in Kidney and Pancreas Transplantation
Lead sponsor
Wake Forest University Health Sciences
Phase
Phase 4
Overall status
Completed
Start date
February 28, 2005
Completion date
November 28, 2011
Enrollment
222 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

graft rejection